Genscript Biotech (SEHK:1548) - Aktienkurs, Nachrichten und Analyse

1548 Aktienübersicht

Die Genscript Biotech Corporation, eine Investment-Holding, ist in der Herstellung und dem Verkauf von biowissenschaftlichen Forschungsprodukten und -dienstleistungen in den Vereinigten Staaten von Amerika, Europa, der Volksrepublik China, Japan, den anderen Regionen des asiatisch-pazifischen Raums und international tätig. Mehr Details

1548 grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	4/6
Künftiges Wachstum	5/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

7.3% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 112.72% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Bei unseren Risikoprüfungen wurden keine Risiken für 1548 festgestellt.

Genscript Biotech Corporation Wettbewerber

WuXi XDC Cayman

SEHK:2268

HK$29.7b

WuXi Biologics (Cayman)

SEHK:2269

HK$62.4b

Frontage Holdings

SEHK:1521

HK$2.0b

Zhejiang Taimei Medical Technology

SEHK:2576

HK$2.9b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Genscript Biotech
Historische Aktienkurse
Aktueller Aktienkurs	HK$10.74
52-Wochen-Hoch	HK$23.60
52-Wochen-Tief	HK$7.43
Beta	1.05
11 Monat Veränderung	-8.98%
3 Monate Veränderung	-11.97%
1 Jahr Veränderung	-50.96%
33 Jahre Veränderung	-71.01%
5 Jahre Veränderung	-43.41%
Veränderung seit IPO	713.64%

Aktuelle Nachrichten und Updates

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Oct 01

Recent updates

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Oct 01

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Sep 16

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Aug 02

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

Aktionärsrenditen

	1548	HK Life Sciences	HK Markt
7D	-1.6%	-9.0%	0.05%
1Y	-51.0%	-58.7%	11.5%

Rendite im Vergleich zur Industrie: 1548 übertraf die Branche Hong Kong Life Sciences , die im vergangenen Jahr eine Rendite von -58.7 erzielte.

Rendite vs. Markt: 1548 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 11.5 erzielte.

Preisvolatilität

Is 1548's price volatile compared to industry and market?
1548 volatility
1548 Average Weekly Movement	9.9%
Life Sciences Industry Average Movement	14.2%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.2%

Stabiler Aktienkurs: 1548 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: 1548Die wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2002	7,284	Weihui Shao	www.genscript.com

Die Genscript Biotech Corporation, eine Investment-Holding, ist in der Herstellung und dem Verkauf von biowissenschaftlichen Forschungsprodukten und Dienstleistungen in den Vereinigten Staaten von Amerika, Europa, der Volksrepublik China, Japan, den anderen Regionen des asiatisch-pazifischen Raums und international tätig. Das Unternehmen ist in vier Segmenten tätig: Biowissenschaftliche Dienstleistungen und Produkte, Biologics Development Services, Industrielle Synthetische Biologieprodukte und Zelltherapie. Das Segment Biowissenschaftliche Dienstleistungen und Produkte bietet Produkte und Dienstleistungen in verschiedenen Kategorien an, darunter DNA-Synthese, Plasmid-DNA-Präparation, molekulares Klonen, Oligonukleotid-Synthese, Protein- und Antikörper-Expression und -Reinigung, Peptid-Synthese, Antikörper-Entwicklung, IVT-RNA-Produktion, Assay-Zelllinien-Entwicklung und Vektor-Packing, molekulare Diagnostik-Tools und Genom-Editing-Tools und -Reagenzien sowie Instrumente für die Proteinanalyse und -Reinigung, Zellisolierung und -aktivierung.

Genscript Biotech Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Genscript Biotech im Vergleich zum Marktanteil des Unternehmens?
1548 grundlegende Statistiken
Marktanteil	HK$22.70b
Gewinn(TTM)	-HK$1.38b
Umsatz(TTM)	HK$7.86b

2.9x

Kurs-Umsatz-Verhältnis

-16.6x

Kurs-Gewinn-Verhältnis

Ist 1548 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
1548 Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$1.01b
Kosten der Einnahmen	US$468.10m
Bruttogewinn	US$541.49m
Sonstige Ausgaben	US$718.50m
Umsatz	-US$177.01m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.083
Bruttomarge	53.63%
Nettogewinnspanne	-17.53%
Schulden/Eigenkapital-Verhältnis	48.1%

Wie hat sich 1548 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

1548 Aktienübersicht

Belohnungen

Risikoanalyse

Genscript Biotech Corporation Wettbewerber

SEHK:2268

HK$29.7b

SEHK:2269

HK$62.4b

SEHK:1521

HK$2.0b

SEHK:2576

HK$2.9b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Recent updates

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Is Genscript Biotech (HKG:1548) Using Debt In A Risky Way?

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

After Leaping 44% Genscript Biotech Corporation (HKG:1548) Shares Are Not Flying Under The Radar

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Erträge & Einnahmen